These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 24138071)

  • 21. Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer.
    Grob TJ; Heilenkötter U; Geist S; Paluchowski P; Wilke C; Jaenicke F; Quaas A; Wilczak W; Choschzick M; Sauter G; Lebeau A
    Breast Cancer Res Treat; 2012 Jul; 134(2):561-7. PubMed ID: 22610646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nuclear TAZ expression associates with the triple-negative phenotype in breast cancer.
    Díaz-Martín J; López-García MÁ; Romero-Pérez L; Atienza-Amores MR; Pecero ML; Castilla MÁ; Biscuola M; Santón A; Palacios J
    Endocr Relat Cancer; 2015 Jun; 22(3):443-54. PubMed ID: 25870251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insulin growth factor receptor-1 expression and loss of PTEN protein predict early recurrence in triple-negative breast cancer.
    Iqbal J; Thike AA; Cheok PY; Tse GM; Tan PH
    Histopathology; 2012 Oct; 61(4):652-9. PubMed ID: 22759273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancers.
    Bayoglu IV; Kucukzeybek BB; Kucukzeybek Y; Varol U; Yildiz I; Alacacioglu A; Akyol M; Demir L; Dirican A; Yildiz Y; Salman T; Tarhan MO
    Biomed Pharmacother; 2015 Mar; 70():190-5. PubMed ID: 25776500
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Akt2 expression is associated with good long-term prognosis in oestrogen receptor positive breast cancer.
    Fohlin H; Pérez-Tenorio G; Fornander T; Skoog L; Nordenskjöld B; Carstensen J; Stål O
    Eur J Cancer; 2013 Apr; 49(6):1196-204. PubMed ID: 23305873
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rim sign and histogram analysis of apparent diffusion coefficient values on diffusion-weighted MRI in triple-negative breast cancer: Comparison with ER-positive subtype.
    Choi Y; Kim SH; Youn IK; Kang BJ; Park WC; Lee A
    PLoS One; 2017; 12(5):e0177903. PubMed ID: 28542297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. S100A14 is a novel independent prognostic biomarker in the triple-negative breast cancer subtype.
    Ehmsen S; Hansen LT; Bak M; Brasch-Andersen C; Ditzel HJ; Leth-Larsen R
    Int J Cancer; 2015 Nov; 137(9):2093-103. PubMed ID: 25912829
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1.
    Pintens S; Neven P; Drijkoningen M; Van Belle V; Moerman P; Christiaens MR; Smeets A; Wildiers H; Vanden Bempt I
    J Clin Pathol; 2009 Jul; 62(7):624-8. PubMed ID: 19561231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overexpressing S100A9 ameliorates NK cell dysfunction in estrogen receptor-positive breast cancer.
    Liu Y; Li M; Fang Z; Gao S; Cheng W; Duan Y; Wang X; Feng J; Yu T; Zhang J; Wang T; Hu A; Zhang H; Rong Z; Shakila SS; Shang Y; Kong F; Liu J; Li Y; Ma F
    Cancer Immunol Immunother; 2024 May; 73(7):117. PubMed ID: 38713229
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Age related influence of triple receptor status on metastatic breast cancer post relapse survival.
    Todorovic-Rakovic N; Neskovic-Konstantinovic Z
    J BUON; 2013; 18(4):851-8. PubMed ID: 24344008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The abundance of the long intergenic non-coding RNA 01087 differentiates between luminal and triple-negative breast cancers and predicts patient outcome.
    De Palma FDE; Del Monaco V; Pol JG; Kremer M; D'Argenio V; Stoll G; Montanaro D; Uszczyńska-Ratajczak B; Klein CC; Vlasova A; Botti G; D'Aiuto M; Baldi A; Guigó R; Kroemer G; Maiuri MC; Salvatore F
    Pharmacol Res; 2020 Nov; 161():105249. PubMed ID: 33068730
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1.
    Engel JB; Honig A; Kapp M; Hahne JC; Meyer SR; Dietl J; Segerer SE
    Arch Gynecol Obstet; 2014 Jan; 289(1):141-7. PubMed ID: 23828443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting Cholesterol Biosynthesis with Statins Synergizes with AKT Inhibitors in Triple-Negative Breast Cancer.
    Hillis AL; Martin TD; Manchester HE; Högström J; Zhang N; Lecky E; Kozlova N; Lee J; Persky NS; Root DE; Brown M; Cichowski K; Elledge SJ; Muranen T; Fruman DA; Barry ST; Clohessy JG; Madsen RR; Toker A
    Cancer Res; 2024 Oct; 84(19):3250-3266. PubMed ID: 39024548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNA copy number alterations and expression of relevant genes in triple-negative breast cancer.
    Han W; Jung EM; Cho J; Lee JW; Hwang KT; Yang SJ; Kang JJ; Bae JY; Jeon YK; Park IA; Nicolau M; Jeffrey SS; Noh DY
    Genes Chromosomes Cancer; 2008 Jun; 47(6):490-9. PubMed ID: 18314908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The three receptor tyrosine kinases c-KIT, VEGFR2 and PDGFRα, closely spaced at 4q12, show increased protein expression in triple-negative breast cancer.
    Jansson S; Bendahl PO; Grabau DA; Falck AK; Fernö M; Aaltonen K; Rydén L
    PLoS One; 2014; 9(7):e102176. PubMed ID: 25025175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.
    Toyama T; Yamashita H; Kondo N; Okuda K; Takahashi S; Sasaki H; Sugiura H; Iwase H; Fujii Y
    BMC Cancer; 2008 Oct; 8():309. PubMed ID: 18950515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases.
    Hohensee I; Lamszus K; Riethdorf S; Meyer-Staeckling S; Glatzel M; Matschke J; Witzel I; Westphal M; Brandt B; Müller V; Pantel K; Wikman H
    Am J Pathol; 2013 Jul; 183(1):83-95. PubMed ID: 23665199
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Androgen receptor status is highly conserved during tumor progression of breast cancer.
    Grogg A; Trippel M; Pfaltz K; Lädrach C; Droeser RA; Cihoric N; Salhia B; Zweifel M; Tapia C
    BMC Cancer; 2015 Nov; 15():872. PubMed ID: 26552477
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical significance of HER2-positive and triple-negative status in small (≤ 1 cm) node-negative breast cancer.
    Gorshein E; Klein P; Boolbol SK; Shao T
    Clin Breast Cancer; 2014 Oct; 14(5):309-14. PubMed ID: 24703318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Triple-negative breast cancer survival in Iranian patients.
    Aghili M; Lashkari M; Farrokhpey AH; Izadi S
    Acta Med Iran; 2013 Sep; 51(8):560-6. PubMed ID: 24026994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.